MRD Detection Development Services

Measurable residual disease (MRD) encompasses the limited population of cancer cells that can persist within a patient's body following cancer treatment. These residual cancer cells exist at levels that cannot be detected through conventional diagnostic techniques like imaging or microscopic examination. The significance of MRD is especially notable in hematological malignancies, such as leukemia and lymphoma, as it serves to evaluate treatment efficacy and anticipate the probability of disease relapse.

Fig. 1. An example of NGS MRD analysis. (Della Starza, I. et al., 2019)

Our Services

Detecting and monitoring MRD is crucial in leukemia management as it provides valuable insights into treatment response, disease progression, and the potential for relapse. Alfa Cytology boasts a team of highly skilled scientists and cutting-edge technologies dedicated to the development of MRD detection methods in leukemia. Our comprehensive services are designed to support researchers in the field, enabling advancements in leukemia treatment.

Development of MRD Detection Methods for Different Types of Leukemia

We provide comprehensive MRD detection method development services for diverse leukemia types. Our expertise encompasses an extensive array of leukemia subtypes, which include, but are not limited to:

Our Technologies for MRD Detection

We develop three main methods for MRD assessment: PCR, flow cytometry, and next-generation sequencing (NGS). Each of these methods has its advantages when it comes to MRD detection. Here are their strengths and limitations for your reference in deciding which technology to develop to accomplish your goals.

Methods	Advantages	Disadvantages
PCR	Widely accessible, relatively affordable, results with quantification relatively quick.	Fresh samples necessary. Sensitivity lower than PCR or NGS.
Flow cytometry	Good sensitivity, usage of DNA, quantitative results.	Specific primers required, baseline reference sample necessary, relatively time and labor intensive.
NGS	High sensitivity, usage of DNA, tracking of clones possible, quantitative results.	Relatively expensive, baseline reference sample necessary, not widely used.

If you are planning to develop MRD detection methods for rare types of leukemia, we offer customized testing services to collaborate with you in exploring effective monitoring strategies. Our team is dedicated to supporting your research and preclinical efforts in advancing MRD detection and developing tailored solutions for improved patient care.

Advantages of Our Services

Advanced technologies enable us to achieve high sensitivity, specificity, and accuracy in MRD assessment.
We have a team of highly skilled scientists with expertise in MRD detection for leukemia.
Our team collaborates closely with researchers to tailor our services to their specific needs.
We adhere to strict quality control measures and validation protocols throughout the assay development process.

Alfa Cytology is committed to the development of methodologies for the detection of MRD in leukemia. We offer comprehensive services to assist researchers in this field and contribute to the progress of leukemia treatment. Our team of experienced experts is well-versed in all approaches and can provide guidance in selecting the most suitable method for your MRD assessment. Feel free to contact us to learn more about our MRD detection services and how we can support your research endeavors in the field of leukemia treatment.

Reference

Della Starza, I.; et al. Minimal residual disease in acute lymphoblastic leukemia: technical and clinical advances. Frontiers in oncology. 2019, 9: 726.

For research use only. Not intended for any clinical use.